Giuseppe Opocher

List of Publications by Year
in descending order

179	10,940	41344 49	31849 101
papers	citations	h-index	g-index

185	185	185	8264
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	11.4	37
2	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2021, , 325-344.	0.1	0
3	Von Hippel-Lindau disease and multispecialist team. Journal of Neurosurgical Sciences, 2021, 65, 213-215.	0.6	0
4	Improving Outcomes in Carotid Body Tumors Treatment: The Impact of a Multidisciplinary Team Approach. Annals of Vascular Surgery, 2021, 75, 315-323.	0.9	6
5	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
6	Pheochromocytomas and paragangliomas in children: Data from the Italian Cooperative Study (TREP). Pediatric Blood and Cancer, 2020, 67, e28332.	1.5	12
7	E2F1 germline copy number variations and melanoma susceptibility. Journal of Translational Medicine, 2019, 17, 181.	4.4	14
8	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2019, , 1-20.	0.1	0
9	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
10	Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. Acta Neuropathologica, 2018, 135, 779-798.	7.7	20
11	Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs, 2018, 29, 102-105.	1.4	17
12	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	3.1	52
13	Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genetics in Medicine, 2018, 20, 1644-1651.	2.4	73
14	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
15	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
16	Copy number variations of E2F1: a new genetic risk factor for testicular cancer. Endocrine-Related Cancer, 2017, 24, 119-125.	3.1	18
17	Impaired Release of Vitamin D in Dysfunctional Adipose Tissue: New Cues on Vitamin D Supplementation in Obesity. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2564-2574.	3.6	40
18	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. Journal of the American Heart Association, 2017, 6, .	3.7	64

#	Article	IF	Citations
19	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149
20	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
21	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	9.6	198
22	Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta Otorhinolaryngologica Italica, 2017, 37, 423-429.	1.5	20
23	Characterization of endolymphatic sac tumors and von Hippelâ€“Lindau disease in the International Endolymphatic Sac Tumor Registry. Head and Neck, 2016, 38, E673-9.	2.0	48
24	[PP.07.12] ARMC5 MUTATIONS IN PATIENTS WITH PRIMARY ALDOSTERONISM AND BILATERAL ADRENAL LESIONS. Journal of Hypertension, 2016, 34, e156-e157.	0.5	0
25	Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro-Oncology, 2016, 18, 1011-1020.	1.2	36
26	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. Journal of Human Hypertension, 2016, 30, 374-378.	2.2	38
27	Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. PLoS ONE, 2016, 11, e0156044.	2.5	45
28	Coexistence of VHL Disease and CPT2 Deficiency: A Case Report. Cancer Research and Treatment, 2016, 48, 1438-1442.	3.0	5
29	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. Journal of Translational Medicine, 2015, 13, 360.	4.4	10
30	Thyroid cancer <scp>GWAS</scp> identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. International Journal of Cancer, 2015, 137, 1870-1878.	5.1	44
31	OECI Accreditation at Veneto Institute of Oncology IOV - IRCCS, General Framework and Multidisciplinary Approach. Tumori, 2015, 101, S38-S41.	1.1	1
32	Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Anti-Cancer Drugs, 2015, 26, 232-235.	1.4	2
33	Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease. European Radiology, 2015, 25, 2025-2032.	4.5	3
34	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
35	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. Endocrine-Related Cancer, 2015, 22, 191-204.	3.1	29
36	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippelâ€“Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial Cancer, 2015, 14, 309-316.	1.9	21

#	Article	IF	Citations
37	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics Journal, 2015, 15, 288-292.	2.0	48
38	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	3.3	11
39	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	3.6	111
40	18F-DOPA PET/CT in the Evaluation of Hereditary SDH-Deficiency Paraganglioma-Pheochromocytoma Syndromes. Clinical Nuclear Medicine, 2014, 39, e53-e58.	1.3	20
41	Role of SDHAF2 and SDHD in von Hippelâ€“Lindau Associated Pheochromocytomas. World Journal of Surgery, 2014, 38, 724-732.	1.6	6
42	Long-term prognosis of patients with pediatric pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 17-25.	3.1	121
43	Opposing effects of HIF1Î± and HIF2Î± on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYCâ€associated factor X. International Journal of Cancer, 2014, 135, 2054-2064.	5.1	72
44	Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension. Endocrine, 2014, 46, 340-346.	2.3	12
45	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	10.7	137
46	Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine, 2014, 45, 469-478.	2.3	80
47	Spectrum of magnetic resonance imaging findings in pancreatic and other abdominal manifestations of Von Hippel-Lindau disease in a series of 23 patients: a pictorial review. JOP: Journal of the Pancreas, 2014, 15, 1-18.	1.5	9
48	Identification and stratification of pheochromocytomas/paragangliomas with SDHx mutations using the succinate to fumarate ratio. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
49	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. American Journal of Pathology, 2013, 182, 350-362.	3.8	35
50	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	3.6	131
51	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	3.5	125
52	Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. Human Molecular Genetics, 2013, 22, 804-815.	2.9	25
53	Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nuclear Medicine Communications, 2013, 34, 1141-1149.	1.1	51
54	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine-Related Cancer, 2013, 20, 477-493.	3.1	52

#	Article	IF	Citations
55	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
56	An Epistatic Interaction between the PAX8 and STK17B Genes in Papillary Thyroid Cancer Susceptibility. PLoS ONE, 2013, 8, e74765.	2.5	9
57	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). Hormone and Metabolic Research, 2012, 44, 411-414.	1.5	71
58	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
59	The Endemic Paraganglioma Syndrome Type 1: Origin, Spread, and Clinical Expression. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E637-E641.	3.6	25
60	Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results. Human Pathology, 2012, 43, 1103-1112.	2.0	21
61	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 905-913.	3.6	95
62	Role of ultrasound and color Doppler imaging in the detection of carotid paragangliomas. Journal of Ultrasound, 2012, 15, 158-163.	1.3	20
63	EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1977-1995.	6.4	223
64	MicroRNA Profiles in Familial and Sporadic Medullary Thyroid Carcinoma: Preliminary Relationships with RET Status and Outcome. Thyroid, 2012, 22, 890-896.	4.5	116
65	RET codon 609 mutations: a contribution for better clinical managing. Clinics, 2012, 67, 33-36.	1.5	7
66	Diagnosi e terapia della sindrome paraganglioma. L Endocrinologo, 2011, 12, 170-178.	0.0	0
67	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	21.4	478
68	Functional Consequences of Succinate Dehydrogenase Mutations. Endocrine Practice, 2011, 17, 64-71.	2.1	15
69	68Ga-DOTA-NOC PET/CT Detects Somatostatin Receptors Expression in von Hippel-Lindau Cerebellar Disease. Clinical Nuclear Medicine, 2011, 36, 64-65.	1.3	21
70	Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas?. Surgery, 2011, 150, 1194-1201.	1.9	26
71	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation, 2011, 32, 51-58.	2.5	117
72	Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. European Journal of Endocrinology, 2011, 164, 971-976.	3.7	86

#	Article	IF	Citations
73	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. Journal of Clinical Oncology, 2011, 29, e171-e174.	1.6	19
74	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	3.6	369
75	First-line sunitinib in patients with renal cell carcinoma (RCC) and von Hippel-Lindau syndrome (VHL).. Journal of Clinical Oncology, 2011, 29, 373-373.	1.6	1
76	Clinical and surgical features of lower brain stem hemangioblastomas in von Hippel-Lindau disease. Acta Neurochirurgica, 2010, 152, 287-292.	1.7	27
77	Are we overestimating the penetrance of mutations in SDHB?. Human Mutation, 2010, 31, 761-762.	2.5	64
78	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics, 2010, 42, 229-233.	21.4	364
79	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. European Journal of Endocrinology, 2010, 163, 369-376.	3.7	53
80	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. Hypertension, 2010, 55, 83-89.	2.7	70
81	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 963.	3.7	1
82	Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology, 2010, 24, 2382-2391.	3.7	179
83	Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. European Journal of Endocrinology, 2010, 163, 301-308.	3.7	111
84	Adrenal and Renal Physiology, and Medical Renal Disease. Journal of Urology, 2010, 184, 1301-1302.	0.4	0
85	Genetics of pheochromocytomas and paragangliomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 943-956.	4.7	62
86	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	7.4	174
87	Urinary Steroid Profiling as a High-Throughput Screening Tool for the Detection of Malignancy in Patients with Adrenal Tumors.. , 2010, , P3-72-P3-72.		1
88	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	7.0	160
89	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	3.6	284
90	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. PLoS Genetics, 2009, 5, e1000637.	3.5	140

#	Article	IF	Citations
91	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research, 2009, 69, 3650-3656.	0.9	178
92	Factors influencing the rising rates of adrenal surgery: analysis of a 25-year experience. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 503-507.	2.4	12
93	Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Familial Cancer, 2009, 8, 379-382.	1.9	14
94	The pheochromocytoma and paraganglioma syndrome: Founder effects and the PGL 1 syndrome. Annales D'Endocrinologie, 2009, 70, 157-160.	1.4	3
95	Surgical Versus Conservative Management for Subclinical Cushing Syndrome in Adrenal Incidentalomas: A Prospective Randomized Study. Annals of Surgery, 2009, 249, 388-391.	4.2	205
96	Molecular characteristics in papillary thyroid cancers (PTCs) with no ¹³¹I uptake. Clinical Endocrinology, 2008, 68, 108-116.	2.4	117
97	RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clinical Endocrinology, 2008, 69, 418-425.	2.4	36
98	Role of the Genetic Study in the Management of Carotid Body Tumor in Paraganglioma Syndrome. European Journal of Vascular and Endovascular Surgery, 2008, 36, 517-519.	1.5	14
99	Gene expression analysis in pheochromocytoma â€“ searching for new pathways involved in the hereditary susceptibility and the malignant outcome. European Journal of Cancer, Supplement, 2008, 6, 160-161.	2.2	0
100	Genetics and Biology of Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 160-165.	1.2	23
101	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
102	La malattia di von Hippel-Lindau. L Endocrinologo, 2007, 8, 102-108.	0.0	0
103	Is the laparoscopic adrenalectomy for pheochromocytoma the best treatment?. Surgery, 2007, 141, 723-727.	1.9	88
104	Laparoscopic adrenalectomy for pheochromocytoma: is it really more difficult?. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1323-1326.	2.4	27
105	Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology, 2006, 65, 699-705.	2.4	130
106	Genetic and Clinical Investigation of Pheochromocytoma: A 22-Year Experience, from Freiburg, Germany to International Effort. Annals of the New York Academy of Sciences, 2006, 1073, 122-137.	3.8	15
107	Familial Nonsyndromic Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 149-155.	3.8	15
108	Paraganglioma Syndrome: SDHB, SDHC, and SDHD Mutations in Head and Neck Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 190-197.	3.8	31

#	Article	IF	Citations
109	Molecular analysis of two uncharacterized sequence variants of the VHL gene. Journal of Human Genetics, 2006, 51, 964-968.	2.3	17
110	Hemangioblastoma of the obex mimicking anorexia nervosa. Neurology, 2006, 67, 178-179.	1.1	13
111	Difficulties in the Mutation Analysis of Plasminogen Gene: A Study in Two Patients with Ligneous Conjunctivitis. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 77-84.	1.7	5
112	A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocrine-Related Cancer, 2006, 13, 525-533.	3.1	25
113	Pheochromocytoma â€“ where are we? Where should we go? A medical and scientific odyssey. Familial Cancer, 2005, 4, 1-1.	1.9	0
114	Pheochromocytoma in von Hippelâ€“Lindau disease and neurofibromatosis type 1. Familial Cancer, 2005, 4, 13-16.	1.9	57
115	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <EMPH TYPE="ITAL">SDHC</EMPH> Gene. JAMA - Journal of the American Medical Association, 2005, 294, 2057.	7.4	309
116	Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology, 2005, 153, 307-315.	3.7	86
117	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
118	Distinct Clinical Features of Paraganglioma Syndromes Associated With <EMPH TYPE="ITAL">SDHB</EMPH> and <EMPH TYPE="ITAL">SDHD</EMPH> Gene Mutations. JAMA - Journal of the American Medical Association, 2004, 292, 943.	7.4	821
119	Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma. Clinical Endocrinology, 2003, 59, 707-715.	2.4	19
120	11 $beta;-hydroxysteroid-dehydrogenase type 2 gene analysis in hypertensive and normotensive subjects. American Journal of Hypertension, 2003, 16, A81.	2.0	0
121	Clinical and Genetic Aspects of Phaeochromocytoma. Hormone Research in Paediatrics, 2003, 59, 56-61.	1.8	16
122	Unilateral Adrenal Tumor, Erectile Dysfunction and Infertility in a Patient with 21-Hydroxylase Deficiency: Effects of Glucocorticoid Treatment and Surgery. Experimental and Clinical Endocrinology and Diabetes, 2003, 111, 41-43.	1.2	12
123	Genetic polymorphism of the renin???angiotensin???aldosterone system and arterial hypertension in the Italian population. Journal of Hypertension, 2003, 21, 1853-1860.	0.5	47
124	Molecular Diagnosis of von Hippel-Lindau Disease. , 2001, 136, 263-270.		0
125	Somatic mosaicism in von Hippel-Lindau disease. Human Mutation, 2000, 15, 114-114.	2.5	66
126	Retinal abnormalities associated with a mutation of the nucleotide 683 in von Hippel-Lindau disease. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 615-620.	1.9	1

#	Article	IF	Citations
127	A Survey on Adrenal Incidentaloma in Italy¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	693
128	A Survey on Adrenal Incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	723
129	Molecular diagnosis of inherited diseases. Clinica Chimica Acta, 1999, 280, 73-80.	1.1	0
130	Natriuretic peptides receptors in human aldosterone-secreting adenomas. Journal of Endocrinological Investigation, 1999, 22, 514-518.	3.3	9
131	Sodium Regulating Hormones at High Altitude: Basal and Post-Exercise Levels¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 570-574.	3.6	36
132	Sodium Regulating Hormones at High Altitude: Basal and Post-Exercise Levels. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 570-574.	3.6	35
133	Adrenal Incidentaloma: An Overview of Hormonal Data from the National Italian Study Group. Hormone Research, 1997, 47, 284-289.	1.8	159
134	Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Journal of Endocrinological Investigation, 1997, 20, 86-89.	3.3	15
135	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 865-869.	3.6	10
136	Effects of highâ€altitude chronic hypoxia on platelet Î± 2 â€receptors in man. European Journal of Clinical Investigation, 1997, 27, 316-321.	3.4	6
137	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 865-869.	3.6	6
138	Expression of type 1 angiotensin II receptors in human aldosteronomas. Endocrine Research, 1995, 21, 189-195.	1.2	20
139	Long-term treatment of mineralocorticoid excess syndromes. Steroids, 1995, 60, 81-86.	1.8	45
140	11Î²-hydroxylase deficiency. Journal of Endocrinological Investigation, 1995, 18, 545-549.	3.3	4
141	Body fluids, atrial volumes and atrial natriuretic peptide during and after high-altitude exposure. Wilderness and Environmental Medicine, 1995, 6, 11-19.	0.9	2
142	Morphology and function of the adrenal zona glomerulosa of transgenic rats TGR [mREN2] 27: Effects of prolonged sodium restriction. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 155-162.	2.5	13
143	Zona glomerulosa of the adrenal gland in a transgenic strain of rat: a morphologic and functional study. Cell and Tissue Research, 1994, 278, 21-28.	2.9	14
144	Apparent mineralocorticoid excess type II. Steroids, 1994, 59, 80-83.	1.8	42

#	Article	IF	Citations
145	3 Adrenal complications of HIV infection. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 769-776.	1.0	9
146	Differential diagnosis in primary aldosteronism. Journal of Steroid Biochemistry and Molecular Biology, 1993, 45, 49-55.	2.5	21
147	Usefulness of Atrial Natriuretic Peptide Assay in Primary Aldosteronism. American Journal of Hypertension, 1992, 5, 811-816.	2.0	5
148	Atrial Natriuretic Peptide (ANP) increases in the mangrove crab Ucides cordatus when exposed to increased environmental salinity. Comparative Biochemistry and Physiology A, Comparative Physiology, 1992, 101, 803-806.	0.6	6
149	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney International, 1992, 41, 813-821.	5.2	20
150	Role of atrial natriuretic peptide in the pathogenesis of sodium retention in IDDM with and without glomerular hyperfiltration. Diabetes, 1992, 41, 936-945.	0.6	7
151	Steroids and hypertension. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 35-44.	2.5	17
152	17-Î±-hydroxylase deficiency in three siblings: short- and long-term studies. Journal of Endocrinological Investigation, 1991, 14, 99-108.	3.3	22
153	Effect of Lacidipine on Pituitary Function in Essential Hypertension. Journal of Cardiovascular Pharmacology, 1991, 18, S26-S28.	1.9	2
154	Hypertensive congenital adrenal enzymatic defects detected by high-performance liquid chromatography of corticosteroids. Journal of Chromatography A, 1991, 553, 201-204.	3.7	7
155	Impaired response to angiotensin II in Type 1 (insulin-dependent) diabetes mellitus. Role of prostaglandins and sodium-lithium countertransport activity. Diabetologia, 1991, 34, 595-603.	6.3	17
156	Resistance to the actions of atrial natriuretic factor in insulin-dependent diabetic hypertensives and improvement with angiotensin converting enzyme inhibitor treatment. Journal of Hypertension, 1991, 9, S264.	0.5	1
157	New Aspects of Mineralocorticoid Hypertension. Hormone Research, 1990, 34, 175-180.	1.8	12
158	Atrial Natriuretic Peptide Infusion in Primary Aldosteronism: Renal, Hemodynamic and Hormonal Effects. American Journal of Hypertension, 1990, 3, 668-673.	2.0	8
159	Atrial natriuretic peptide in Cushingâ€™s disease. Journal of Endocrinological Investigation, 1990, 13, 133-137.	3.3	7
160	A sensitive immunoassay for nerve growth factor determination. Pharmacological Research, 1990, 22, 463.	7.1	0
161	Impact of High Performance Liquid Chromatography on Assay of Steroid Hormones. Annals of the New York Academy of Sciences, 1990, 595, 480-483.	3.8	3
162	Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. Diabetes, 1990, 39, 289-298.	0.6	25

#	Article	IF	Citations
163	Acute and Chronic Effect of Nifedipine in Primary Aldosteronism. Clinical and Experimental Hypertension, 1989, 11, 1263-1272.	0.3	17
164	Lack of aldosterone inhibition by atrial natriuretic factor in primary aldosteronism: in vitro studies. Journal of Endocrinological Investigation, 1989, 12, 13-17.	3.3	8
165	Atrial natriuretic factor in hypertensive and normotensive insulin-dependent diabetics. Journal of Hypertension, 1989, 7, S236-237.	0.5	5
166	Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. Journal of Endocrinological Investigation, 1987, 10, 377-382.	3.3	20
167	Effect of Verapamil on aldosterone secretion in primary aldosteronism. Journal of Endocrinological Investigation, 1987, 10, 491-494.	3.3	16
168	Renin-Angiotensin-Aldosterone System: A Long-Term Follow-Up Study in 17Î±-Hydroxylase Deficiency Syndrome (17OHDS). Clinical and Experimental Hypertension, 1986, 8, 773-780.	0.3	9
169	Aldosterone, Calcium, and Hypertension. American Journal of Nephrology, 1986, 6, 33-39.	3.1	7
170	Opioid Modulation of Normal and Pathological Human Chromaffin Tissue*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 577-582.	3.6	17
171	Effect of Verapamil on the Aldosterone-Stimulating Properties of Metoclopramide: In Vitro and In Vivo Studies. Hormone and Metabolic Research, 1986, 18, 775-778.	1.5	4
172	Effect of Ketanserin in Primary Aldosteronism. Journal of Cardiovascular Pharmacology, 1985, 7, 172-175.	1.9	22
173	Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. The Journal of Steroid Biochemistry, 1983, 19, 531-536.	1.1	3
174	Insulin Resistance in Cushingâ€™s Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 529-536.	3.6	146
175	Peripheral and Renal Vein Plasma Renin Activity in Hypertensive Urological Patients. British Journal of Urology, 1982, 54, 348-353.	0.1	8
176	Mineralocorticoid hypertension due to a nasal spray containing 9Î±-fluoroprednisolone. American Journal of Medicine, 1981, 71, 352-357.	1.5	36
177	Effect of indomethacin on urinary kallikrein excretion in Barttersâ€™s syndrome of the adult. Journal of Endocrinological Investigation, 1981, 4, 17-20.	3.3	4
178	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. Hormone and Metabolic Research, 1981, 13, 464-467.	1.5	20
179	217. Effect of metoclopramide on plasma aldosterone: in vivo and in vitro studies. The Journal of Steroid Biochemistry, 1978, 9, 858.	1.1	0